These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 32181540)
1. National pharmacovigilance programs in Arab countries: A quantitative assessment study. Alshammari TM; Alenzi KA; Ata SI Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1001-1010. PubMed ID: 32181540 [TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries. Wilbur K Drug Saf; 2013 Jan; 36(1):25-30. PubMed ID: 23315293 [TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemic. Al-Zubiedi SA; Younus M; Al-Khalidi S; Ekilo M; Alshammari TM Expert Opin Drug Saf; 2023 Feb; 22(2):165-174. PubMed ID: 35915555 [TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance activities in ASEAN countries. Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034 [TBL] [Abstract][Full Text] [Related]
5. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey. Qato DM Int J Pharm Pract; 2018 Jun; 26(3):210-221. PubMed ID: 28737220 [TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries. Alshammari TM; Mendi N; Alenzi KA; Alsowaida Y Drug Saf; 2019 Jul; 42(7):849-868. PubMed ID: 31006085 [TBL] [Abstract][Full Text] [Related]
7. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi. Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447 [TBL] [Abstract][Full Text] [Related]
8. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398 [TBL] [Abstract][Full Text] [Related]
9. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055 [TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480 [TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives. Jose J; Rafeek NR Ther Innov Regul Sci; 2019 Nov; 53(6):781-786. PubMed ID: 30554527 [TBL] [Abstract][Full Text] [Related]
12. Current status of pharmacovigilance regulatory structures, processes, and outcomes in the Asia-Pacific region: Survey results from 15 countries. Shin JY; Shin E; Jeong HE; Kim JH; Lee EK Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):362-369. PubMed ID: 30648304 [TBL] [Abstract][Full Text] [Related]
13. Strengths and Weaknesses of the Pharmacovigilance Systems in Three Arab Countries: A Mixed-Methods Study Using the WHO Pharmacovigilance Indicators. Garashi H; Steinke D; Schafheutle E Int J Environ Res Public Health; 2022 Feb; 19(5):. PubMed ID: 35270208 [TBL] [Abstract][Full Text] [Related]
14. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924 [TBL] [Abstract][Full Text] [Related]
15. Implementation of a Pharmacovigilance System in a Resources-Limited Country in the Context of COVID-19: Lebanon's Success Story. Abbas H; Zeitoun A; Watfa M; Karam R Ther Innov Regul Sci; 2023 Mar; 57(2):178-185. PubMed ID: 36109433 [TBL] [Abstract][Full Text] [Related]
16. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil. Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977 [TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence in Pharmacovigilance and COVID-19. Bhardwaj K; Alam R; Pandeya A; Sharma PK Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726 [TBL] [Abstract][Full Text] [Related]
18. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794 [TBL] [Abstract][Full Text] [Related]
19. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471 [TBL] [Abstract][Full Text] [Related]
20. Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country. Nguyen KD; Nguyen PT; Nguyen HA; Roussin A; Montastruc JL; Bagheri H; Olsson S Drug Saf; 2018 Feb; 41(2):151-159. PubMed ID: 28975584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]